Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affibody AB

www.affibody.com

Latest From Cerulean Pharma Inc.

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Depomed CEO, Two Board Members Out In Settlement With Investor

Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.

Commercial Companies

Deal Watch: BioLineRx, Ono, Vedantra Ink Separate Cancer Immunotherapy Pacts

BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.

Commercial Deals

Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré

Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Affibody AB
  • Senior Management
  • David Bejker, CEO
    Johan Stuart, CFO
    Fredrik Frejd, VP, Rsch.
  • Contact Info
  • Affibody AB
    Phone: (46) 8 59 88 38 00
    Gunnar Asplunds Allé 24
    Solna, SE-171 63
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register